Reading UNCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UNCY free→Reading UNCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UNCY free→QuarterlyIQ Insights · UNCY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. As previously reported, Unicycive Therapeutics, Inc. (the “Company”) entered into a Sales Agreement, dated November 13, 2024, with Guggenheim Securities, LLC, as sales agent (the “Agent”) as amended by Amendment No. 1 to Sales Agreement dated November 14, 2025, between the Company and the Agent (as amended, the “Sales Agreement”), to sell shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price…
Results of Operations and Financial Conditions. On May 12, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On April 6, 2026, Gaurav Aggarwal, a director of Unicycive Therapeutics, Inc. (the “Company”), resigned from the Board of Directors of the Company. Dr. Aggarwal’s resignation was not a result of any disagreement with the Company or its management or Board on any matter related to the Company’s operations, policies, or practices. The Company expres…
Results of Operations and Financial Conditions. On March 30, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Conditions. On November 12, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…
Results of Operations and Financial Condition On October 28, 2025, Unicycive Therapeutics, Inc. (the “Company”) issued a press release that included information with respect to certain preliminary, unaudited financial results of the Company. While the Company has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $42 million of cash and cash equivalents as of September 30, 2025. This estimate is preliminar…
Other Events On October 28, 2025, the Company issued a press release announcing an update from its meeting with the U.S. Food and Drug Administration and timing of the resubmission of its New Drug Application for Oxylanthanum Carbonate following receipt of a Complete Response Letter on June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Other Events. On August 15, 2025, Unicycive Therapeutics, Inc. (the “Company”) became aware of a lawsuit purporting to be a securities class action which was filed in United States District Court for the Northern District of California against the Company and certain of its officers. This action alleges violations of the federal securities laws in connection with public statements by the Company relating to its new drug application for oxylanthanum carbonate phosphate binder for the treatment…
Results of Operations and Financial Conditions. On August 14, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Other Events . On June 30, 2025, Unicycive Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. While the Company ha…
Results of Operations and Financial Condition The information set forth below in the second paragraph of
Material Modification to Rights of Security Holders. To the extent required by
Results of Operations and Financial Conditions. On May 14, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Results of Operations and Financial Conditions. On March 31, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2024 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.